Core Viewpoint - The company intends to acquire a 19.0526% stake in Beijing Health from Chengdu Deyixin Huaxin Investment Partnership for 67.56052 million yuan, increasing its ownership in Beijing Health from 80.9474% to 100% [1] Group 1: Acquisition Details - The acquisition will be funded through the company's own or raised funds [1] - The stake corresponds to Chengdu Deyixin's paid-in capital of 67.37 million yuan [1] Group 2: Company Background - Beijing Health was established in December 2020 and serves as the sales and promotion platform for the company's main products [1] - The company focuses on the circulation of high-quality pharmaceuticals in the fields of digestive and anti-infective drugs [1] Group 3: Financial Performance and Strategic Rationale - Beijing Health has achieved profitability and its future profit potential and operational risks are reliably estimable [1] - The acquisition is aimed at optimizing resource allocation, enhancing decision-making efficiency, and promoting synergistic development with quality subsidiaries [1] - This move aligns with the company's long-term development strategy [1]

Group 1 - The company announced that its sixth board meeting was held on February 12, 2026, in two locations: Shandong Province and Shanghai, using a combination of on-site and remote voting methods [1] - The meeting reviewed proposals regarding the acquisition of minority shareholder equity in a controlling subsidiary and related transactions [1] Group 2 - The company experienced a dramatic fluctuation in net profit, increasing ninefold before suddenly reporting a loss exceeding 200 million [1] - The chairman personally contributed 50 million to cover the financial shortfall, raising questions about the company's financial management [1] - There is uncertainty regarding the whereabouts of 5 billion in trust financial products, leading to confusion among shareholders [1]

目 录 | 一、审计报告……………………………………………………… 第 | 1—3 页 | | --- | --- | | 二、财务报表……………………………………………………… 第 | 4—11 页 | | （一）合并资产负债表…………………………………………… | 第 4 页 | | （二）母公司资产负债表………………………………………… | 第 5 页 | | （三）合并利润表………………………………………………… | 第 6 页 | | （四）母公司利润表……………………………………………… | 第 7 页 | | （五）合并现金流量表…………………………………………… | 第 8 页 | | （六）母公司现金流量表………………………………………… | 第 9 页 | | （七）合并所有者权益变动表……………………………………第 | 10 页 | | （八）母公司所有者权益变动表…………………………………第 | 11 页 | | 三、财务报表附注…………………………………………………第 | 12—52 页 | | 四、附件……………………………………………………………第 | 53—56 页 | | （ ...

本资产评估报告依据中国资产评估准则编制 罗欣药业集团股份有限公司拟受让罗欣健康科技 ( 北京 )有限公司 19.0526%股权所涉及的罗欣健康 科技( 北京 )有限公司股东全部权益价值 资产评估报告 东 洲评报字【2026】第 0197 号 ( 报告书 ) 共1册 第1册 上海东 洲资 产评估有限 公司 2026年2月5日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 3131020001202600329 | | --- | --- | | 合同编号: | 东洲评委(202601041)号 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 东洲评报字【2026】第0197号 | | 报告名称: | 罗欣药业集团股份有限公司拟受让罗欣健康科技(北京)有限公 司19.0526%股权所涉及的罗欣健康科技(北京)有限公司股东全 部权益价值 | | 评估结论: | 354,600,000.00元 | | 评估报告日: | 2026年02月05日 | | 评估机构名称: | 上海东洲资产评估有限公司 | | 签名人员: 金容佳 | 刘思卿 (资产评估师) 正式会员 编号:312 ...

证券代码：002793 证券简称：罗欣药业 公告编号：2026-015 罗欣药业集团股份有限公司 关于受让控股子公司少数股东股权暨关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、罗欣药业集团股份有限公司（以下简称"公司""罗欣药业"）拟以自 有资金或自筹资金 6,756.052 万元受让成都得怡欣华股权投资合伙企业（有限合 伙）（以下简称"成都得怡"）持有的罗欣健康科技（北京）有限公司（以下简 称"北京健康""标的公司"）19.0526%股权，对应成都得怡实缴出资金额为 6,737 万元，交易完成后，公司对北京健康持股比例将由 80.9474%升至 100%。 截至目前，成都得怡及其一致行动人合计持有公司 5%以上股份，属于公司 关联方，根据《深圳证券交易所股票上市规则》等相关规定，本次交易构成关联 交易。 3、审议程序 2026 年 2 月 12 日，公司召开第六届董事会第二次会议，以 5 票同意、0 票 反对、0 票弃权、2 票回避的表决结果，审议通过《关于受让控股子公司少数股 东股权暨关联交易的议案》，关联董事刘振腾、刘振 ...

公司本次受让控股子公司少数股东股权是基于公司战略布局及罗欣健康科 技（北京）有限公司发展需要做出的决定，符合公司战略规划。本次关联交易遵 循了自愿、公平、合理的原则，定价公平合理，符合有关法律、法规的规定，关 联交易决策程序合法、合规，不存在损害公司和股东特别是中小股东利益的情况。 具体内容详见同日刊登于巨潮资讯网（http://www.cninfo.com.cn）、《上海证券报》 的《关于受让控股子公司少数股东股权暨关联交易的公告》。 证券代码：002793 股票简称：罗欣药业 公告编号：2026-014 罗欣药业集团股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2026 年 2 月 12 日，罗欣药业集团股份有限公司（以下简称"公司"）第六 届董事会第二次会议在山东省临沂高新技术产业开发区罗七路管理中心三楼会 议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合的方 式召开。会议通知已于 2026 年 2 月 6 日以电话、专人送达、电子邮件等方式发 出。本次会议应出席董事 ...

Core Viewpoint - The company, Luoxin Pharmaceutical, is expected to significantly narrow its net profit loss for 2025, while its innovative drug, Tegolix, is experiencing commercial growth and key advancements in its R&D pipeline [1][2]. Financial Performance - The company forecasts a net profit loss for 2025 to be between -250 million to -340 million yuan, a substantial improvement from the -965 million yuan loss in 2024. The expected non-recurring net profit loss is projected to be between -260 million to -350 million yuan [2]. Business Development - The innovative drug Tegolix has been included in the 2025 National Medical Insurance Directory for three major indications, removing payment barriers. In the first half of 2025, the number of hospitals carrying the product surged by nearly 2,500, with sales volume increasing approximately 140% year-on-year [3]. Product R&D Progress - The injectable LX22001 is currently in Phase II clinical trials, while the Phase III clinical research report for Pucanide has been finalized and is moving towards commercialization. These advancements in innovative drugs may impact the company's long-term growth trajectory [4]. Company Status - The company completed the transfer of 100% equity in Lekang Pharmaceutical for 62.5 million yuan in January 2026 and finalized the transfer of 20% equity in Luoxin Anruo Weita in December 2025. These divestitures are expected to reduce non-operating losses, gradually alleviating future loss impacts [5]. Capital Increase - In September 2025, the company announced a plan to raise no more than 842 million yuan through a private placement, primarily for innovative drug R&D and raw material expansion projects. If implemented, this plan could optimize production capacity and support R&D investments [6]. International Expansion - As of the first half of 2025, the company has obtained over a hundred overseas registration approvals in emerging markets along the "Belt and Road" initiative, as well as in Latin America and Africa, indicating a continuous expansion of its international footprint [7]. Institutional Perspective - Zhongyou Securities initiated coverage on Luoxin Pharmaceutical in January 2026, projecting a return to revenue growth from 2025 to 2027, with a potential net profit of 320 million yuan by 2027, and assigned a "buy" rating. This external perspective may provide insights, but company announcements should be prioritized [8].

Core Viewpoint - Luo Xin Pharmaceutical (002793) reported that as of February 10, 2026, the total number of shareholders is 38,789 [1] Group 1 - The company is actively engaging with investors through an interactive platform [1] - The total number of shareholders indicates a growing interest in the company's stock [1]

Core Viewpoint - The company, 罗欣药业, expects a net profit attributable to shareholders of approximately -340 million to -250 million yuan for the fiscal year 2025, compared to a loss of 965 million yuan in the same period last year [1] Financial Performance - The primary reason for the performance change is the company's strategic focus on the pharmaceutical industrial sector, particularly in the digestive system field, driven by the rapid growth of its core innovative drug, 替戈拉生片 (brand name: 泰欣赞) [1] - The company still anticipates a loss for 2025 due to ongoing underperformance of 上药罗欣 and confirmed fair value losses on related financial liabilities, which are classified as non-recurring gains and losses [1] Business Strategy - The company has initiated procedures to dispose of the loss-making businesses related to 乐康制药 and 罗欣安若维他, but the operational losses prior to the completion of these sales continue to impact the current period's performance [1] - The impact of these losses is expected to decrease once the disposals are finalized [1]

Core Viewpoint - Luoxin Pharmaceutical is expected to significantly improve its financial performance in 2025, with a projected net profit loss narrowing to between -340 million and -250 million yuan, compared to -965 million yuan in 2024, indicating a positive turnaround in operations driven by strategic focus and core product growth [1][2] Financial Performance - The company forecasts a net profit loss of -340 million to -250 million yuan for 2025, a substantial improvement from the previous year's loss of -965 million yuan [1] - The adjusted net profit loss, excluding non-recurring items, is expected to be between -350 million and -260 million yuan, compared to -768 million yuan in the prior year [1] - Gross margin for the first three quarters of 2025 has increased to 51.8%, and operating cash flow has turned positive, reaching 280 million yuan, indicating enhanced profitability [2] Product Development and Market Position - Luoxin Pharmaceutical's core innovative drug, Tegoprazan, has entered a rapid growth phase, benefiting from its unique advantages such as quick onset of action and minimal drug interactions, achieving a significant commercial milestone in China [2] - The drug has achieved full coverage under the new national medical insurance directory for its three indications, greatly boosting sales [2] - The company holds over 350 invention patents and has received multiple registrations in international markets, showcasing its competitive edge globally [2] Strategic Focus - The company has established a robust pipeline with a focus on innovative drugs and differentiated generic drugs, ensuring a sustainable growth model [2] - Ongoing research includes new indications for Tegoprazan and the orderly advancement of subsequent products like LX22001 [2] - The company has completed the consistency evaluation for existing marketed products and is continuously reducing costs through integrated raw material and formulation processes [2]